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The Ubiquitin-Proteasome-System 
 
The discovery of the ubiquitin conjugation pathway and the identification of the 26S 
proteasome as the machine degrading polyubiquitinated proteins opened a view into a 
completely new world of cellular regulation.  Proteolysis, previously considered as unspecific 
and thus less important, suddenly evolved into a field of pre-eminent importance. Central 
cellular processes such as signal transduction, metabolic regulation, cell cycle control, 
development, apoptosis, protein quality control, or antigen presentation were found to depend 
on a functional ubiquitin-proteasome-system. Defects in this system lead to severe diseases as 
for instance inflammation, cancer or neurodegeneration. It is therefore of utmost importance 
to understand the players of the system, their function and their molecular mechanism in the 
different cellular processes comprehensively.  
 
When in 2004 the first review issue of Biochimica et Biophysica Acta Molecular Cell 
Research on the ubiquitin-proteasome machinery appeared, the field had started to blossom.  
Ten years later, improved and novel biochemical, cell biological and structural approaches 
have led to a wealth of new insights into the system. This has led to a significantly deeper 
understanding of many cellular processes and connected diseases. For example good 
structural knowledge was only available of the 20S core particle, the proteolytically active 
cylinder of the proteasome. However, recently the structural and mechanistic features of the 
19S regulatory particle and its cooperation with the protease core begin to unravel. In 
addition, we begin to see that ubiquitin is not a single “word“ but the unit of a whole 
biological ‘language’. Key to this complex ‘language’ is the type of modification of a specific 
substrate protein. It can vary between mono-ubiquitination, multiple monoubiquitination and 
modification by ubiquitin chains. Since ubiquitin chains are characterized by the lysine 
residues in ubiquitin used for the ubiquitin-ubiquitin linkage, a variety of different chains can 
be used to modify target molecules. Then, the dynamics of building, processing and 
disassembly of ubiquitin chains is still far from being understood. The number of substrate 
proteins and accordingly the number of cellular processes these proteins are involved in, is 
steadily increasing. Additional ubiquitin like proteins (UBL´s) interconnecting with the 
ubiquitin language diversify and refine this modification even more. Separate UBL activation- 
and ligation  systems operate and in certain cases UBL (SUMO) and ubiquitin modification is 
intertwined. Together with this we learn about an increasing number of diseases which are 
connected with the system. We have to learn about the mistakes in the ubiquitin language as 
well as in the processing and degradation machineries to be able to understand the molecular 
basis of the diseases, and hopefully some time from now will be able to find drugs to combat 
them. The discovery of the proteasome inhibitors bortezomib  ( Velcade ® ) and carfilzomib ( 
Kyprolis ® ) for treatment of multiple myeloma is a promising start. 
 
The reviews in this volume will provide insights into our present knowledge of the 
proteasome, its components, its assembly and its dynamics in the cell. Furthermore, the 
varying components of the ubiquitin-proteasome system acting in different cellular processes 
as well as the dynamics of ubiquitin linkage, assembly and disassembly will be highlighted. 
Finally, diseases linked with defects in the system will be presented.   
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